Elisabeth is the VP CVMD GMed – the Head of late phase Cardiovascular and Metabolic development unit within AZ. She is leading the development activities across the AZ late phase cardiovascular (mainly Brilinta, Crestor and Epanova), diabetes (mainly Onglyza, Forxiga, Byetta, Bydureon and combinations) and CKD (roxadustat and tenapenaror in development) portfolio.

Prior to taking on this role in June 2012, Elisabeth was Global Product VP for dapagliflozin (approved as Forxiga in Europe and many other countries, including Australia, and as Farxiga in the US), and led the development of this first-in-class drug in partnership with Bristol Myers Squibb. She has also been involved in the delivery of key late phase CVMD and GI projects like Crestor, Nexium, Onglyza, Brilinta and others. She led the team that delivered several CV outcomes studies for Crestor (CORONA, JUPITER, AURORA).

Elisabeth is an endocrinologist by training and an associate professor of medicine at Uppsala University, and was Head of the Diabetes and Endocrinology Unit at the University Hospital, Uppsala, where she spent 15 years in clinical practice and diabetes research, before joining AZ in 2002.